Article Text

PDF

P73 Preliminary results of the Study of Acute Liver Transplant (SALT): NSAID exposure and risk of acute liver failure leading to transplantation in 7 European countries
  1. D Thorburn1,
  2. E Gulmez2,
  3. S Lignot2,
  4. D Larrey3,
  5. C de Vries4,
  6. S Perez-Gutthann5,
  7. J L Montastruc6,
  8. M Sturkenboom7,
  9. J Benichou8,
  10. G Velo9,
  11. A Caputi10,
  12. F Salvo2,
  13. F Hamoud2,
  14. S Micon2,
  15. R Lassalle2,
  16. J Jove2,
  17. G P Pageaux3,
  18. Y Horsmans11,
  19. J Bernuau12,
  20. F Bissoli13,
  21. B Stricker7,
  22. A Gatta14,
  23. E Monteiro15,
  24. I Vafiadis16,
  25. A McCormick17,
  26. H Metselaar7,
  27. E Sen7,
  28. A Nightingale4,
  29. P Blin2,
  30. N Moore2
  1. 1Royal Free NHS Trust, Liver Unit
  2. 2University Bordeaux Segalen, Bordeaux
  3. 3CHU St Eloi Hospital, Montpellier
  4. 4Bath University, Bath
  5. 5RTI Health Solutions, Barcelona
  6. 6CHU de Toulouse, Toulouse
  7. 7Erasmus University MC, Rotterdam
  8. 8CHU de Rouen, Rouen
  9. 9University of Verona, Verona
  10. 10Policlinico Universitario, Messina
  11. 11Louvain Catholic University, Louvain
  12. 12Beaujon Hospital, Clichy
  13. 13Clinica San Gaudenzio, Novara
  14. 14Padua University Hospital, Padua
  15. 15Santa Maria Hospital, Lisbon
  16. 16Athens University School of Medicine, Laiko General Hospital, Athens
  17. 17St. Vincent's University Hospital, Dublin

Abstract

Introduction The risk of acute liver failure (ALF) related to NSAIDs is still discussed and the European Medicines Agency requested a study investigating this. University Bordeaux Segalen conducted the study independently.

Aim To estimate the incidence rates of ALF leading to registration for liver transplantation (LT) in patients exposed to NSAIDs.

Method Multinational, multicentre, case-population study performed in France, Greece, Ireland, Italy, the Netherlands, Portugal, and the UK retrospectively evaluating a 3-year period (2005–2007) in adults. Data of ALF cases were sought through liver transplant registries and hospital records. Demographic and clinical data were collected for all ALF cases and drug use information was collected for the exposure window of 30 days prior to index date (ID, initial symptoms of liver disease). For ALF cases exposed to NSAIDs (ATC code M01A), rate per million treatment-years (tt-yrs) was calculated using sales data from IMS. Poisson CIs (95% CI) were estimated.

Results In the seven participating countries, 62 LT centres were identified and contacted, five were excluded (four paediatric, one oncology), and 50 actively contributed data before database lock. Among the 8824 patients identified from LT lists for the period 2005–2007, 500 were cases of ALF: 197 with identified clinical cause, 21 with incomplete or unavailable medical files, and 241 drug-exposed without identified clinical cause. Among the latter, 34 were exposed to at least one NSAID, 123 exposed to other drugs, and 84 were acute drug intoxications. Mean age of NSAID-exposed ALF cases was 43.8 years, 24 were female. Event rates per million treatment-years were 4.4 (95% CI 3.0 to 6.1) for all NSAIDs pooled, 5.6 (2.4 to 11.1) for nimesulide (8 cases), 5.8 (2.8 to 10.6) for ibuprofen (10 cases), 4.5 (1.5 to 10.4) for diclofenac (5 cases), and 4.7 (1.0 to 13.6) for ketoprofen (3 cases). 71 of the 157 non-intoxication cases had been exposed to paracetamol (9.8 per million treatment-years, 95% CI 7.7 to 12.4), and 83 of the 84 intoxications.

Conclusion In seven countries over 3 years only 34 NSAID-exposed ALF cases leading to registration for LT were identified with no differences in incidence rates per million tt-yrs among the most used NSAIDs. Non-overdose paracetamol-associated liver failure was twice more common.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.